Showing 1511-1520 of 1692 results for "".
- One-Time Gene Therapy Delivered Neurosurgically Delivered to Striatum Provided Sustained Motor Function Improvements in Parkinson Diseasehttps://practicalneurology.com/news/one-time-gene-therapy-delivered-neurosurgically-delivered-to-striatum-provided-sustained-motor-function-improvements-in-parkinson-disease/2469381/
- New Formulation of Dihydroergotamine for Acute Migraine Treatment Submitted to FDA for Approvalhttps://practicalneurology.com/news/new-drug-application-for-dihydroergotamine-mesylate-acute-migraine-treatment-submitted-to-fda/2469425/In the phase 3 open-label STOP 301 study (NCT03557333), participants with migraine who treated attacks with dihydroergotamine mesylate (DHE) (inp104; Impel Neuropharma, Seattle, CA) had pain relief (66.3%), pain freedom (38%), and free
- Evidence Shows Telemedicine With Neurologists Is Effective For Patients and Caregivershttps://practicalneurology.com/news/evidence-shows-telemedicine-with-neurologists-is-effective-for-patients-and-caregivers/2469091/According to a review of the evidence conducted by the American Academy of Neurology (AAN) and published in the journal Neurology, seeing a neurologist by video may be as effective as an in-person visit.
- Clinical Trial of Nanocrystalline Gold for Amyotrophic Lateral Sclerosis Completes Double-Blinded Phasehttps://practicalneurology.com/news/clinical-trial-of-nanocrystalline-gold-for-amyotrophic-lateral-sclerosis-completes-double-blinded-phase/2469688/All patient visits have been completed in the phase 2 study (NCT04098406) of catalytically active gold nanocrystals (Clene Nanomedicine, Salt Lake City, UT) for early-stage amyotrophic lateral scl
- Wrist-Worn Neurostimulation Device for Hand Movement Rehabilitation after Stroke or Spinal Injury Receives FDA Clearancehttps://practicalneurology.com/news/wrist-worn-neurostimulation-device-for-hand-movement-rehabilitation-after-stroke-or-spinal-injury-receives-fda-clearance/2473788/The Food and Drug Administration (FDA) has granted 510(K) clearance to NeuStim (Neuvotion, Stamford, CT), a noninvasive, surgery-free wearable neurostimulation device used to aid in hand movement recovery in patients who have experienced a stroke or spinal cord injury (SCI). The device can scan m
- A New Embolic Material Stops the Flow of Blood to Brain Tumorshttps://practicalneurology.com/news/a-new-embolic-material-stops-the-flow-of-blood-to-brain-tumors/2470534/NeoCast (Arsenal Medical, Waltham, MA), a solvent-free, nonadhesive liquid embolic material designed to stop blood flow to brain tumors, was shown to be feasible in providing complete occlusion of targeted vessels. The material was also shown to achieve safety endpoints. Results of the EMBO-01 cl
- XBiotech Launches Study of Hutrukin Therapy for Injury Reduction After Ischemic Stroke Reperfusionhttps://practicalneurology.com/news/xbiotech-launches-study-of-hutrukin-therapy-for-injury-reduction-after-ischemic-stroke-reperfusion/2470179/XBiotech Inc. (Austin, TX) announced it has enrolled the first patient in a randomized, open-label, placebo-controlled dose escalation clinical study to evaluate the safety and pharmacokinetics of Hutrukin Therapy, a human derived, modification-free antibody. The company is developing Hutrukin as
- New Social Networking Platform for the Multiple Sclerosis Communityhttps://practicalneurology.com/news/new-social-networking-platform-for-the-multiple-sclerosis-community/2469254/A new free anonymous AI-powered social networking and navigation platform, BelongMS (Belong.Life, New York, NY), has been launched for individuals with multiple sclerosis (MS), caregivers, and healthcare professionals. The app can be downloaded for Android and iOS. The new app follows t
- Alemtuzumab Effective for Treatment of MS Over 8 Years of Follow Uphttps://practicalneurology.com/news/alemtuzumab-effective-for-treatment-of-ms-over-8-years-of-follow-up/2468817/After 8 years of treatment with alemtuzumab (Lemtrada; Sanofi, Bridgewater, NJ), patients treated with 3 or more courses of the drug had an annualized relapse rate (ARR) of 0.18%, 85% of patients have been free of relapses, and 70% of patients had stable or improved scores on the Expanded Disabil
- Gabapentin Users Experienced Fewer Falls than Duloxetine Usershttps://practicalneurology.com/news/gabapentin-users-experienced-fewer-falls-than-duloxetine-users/2470943/Treatment with gabapentin may be associated with a reduced risk of falls compared with duloxetine, according to study results published in the Annals of Internal Medicine. Gabapentin users demonstrated significantly fewer fall-related healthcare visits compared with duloxetine users and an approx